Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Respiratory Research
Published in: Respiratory Research 1/2021

01-12-2021 | Obesity | Research

Visceral adiposity index is associated with lung function impairment: a population-based study

Authors: Sunyue He, Jie Yang, Xiaoyong Li, Hongxia Gu, Qing Su, Li Qin

Published in: Respiratory Research | Issue 1/2021

Login to get access

Abstract

Background

The effects of visceral adiposity on decreased lung function have drawn much attention. Recently, the visceral adiposity index (VAI) has been proposed as a visceral fat distribution and dysfunction marker. However, the relationship between the VAI and lung function has not been investigated. The objective of the study was to analyze the association between the VAI and lung function and evaluate the potential of VAI as a predictor of lung function.

Methods

We collected data from a population-based study of 1786 subjects aged 40 years or older. All subjects completed a questionnaire and underwent anthropometric measurements and laboratory tests. Linear and logistic regression models were developed to assess the association between the VAI and lung function.

Results

The VAI was inversely related to FVC%predicted in men and negatively associated with both FVC%predicted and FEV1%predicted in women. In the linear regression analysis, the decrease in FVC%predicted associated with each 10% increase in the VAI was 1.127% in men and 1.943% in women; the decrease in FEV1%predicted associated with each 10%increase in the VAI was 0.663% in men and 1.738% in women. Further regression analysis revealed that the VAI was positively correlated with FVC and FEV1 impairment in women.

Conclusions

We were the first to show a clear correlation between the VAI and lung function impairment in the Chinese population. The VAI could be a simple and reliable approach in daily practice, and individuals, especially women with a high VAI, should receive additional screening and preventive interventions for respiratory disease.
Literature
1.
Schünemann HJ, Dorn J, Grant BJ, Winkelstein W Jr, Trevisan M. Pulmonary function is a long-term predictor of mortality in the general population: 29-year follow-up of the Buffalo Health Study. Chest. 2000;118:656–64.PubMedCrossRef
2.
Leone N, Courbon D, Thomas F, Bean K, Jégo B, Leynaert B, et al. Lung function impairment and metabolic syndrome: the critical role of abdominal obesity. Am J Respir Crit Care Med. 2009;179:509–16.PubMedCrossRef
3.
Canoy D, Luben R, Welch A, Bingham S, Wareham N, Day N, et al. Abdominal obesity and respiratory function in men and women in the EPIC-Norfolk Study, United Kingdom. Am J Epidemiol. 2004;159:1140–9.PubMedCrossRef
4.
Goudarzi H, Konno S, Kimura H, Makita H, Matsumoto M, Takei N, et al. Impact of abdominal visceral adiposity on adult asthma symptoms. J Allergy Clin Immunol Pract. 2019;7(1222–29):e5.
5.
Pekkarinen E, Vanninen E, Länsimies E, Kokkarinen J, Timonen KL. Relation between body composition, abdominal obesity, and lung function. Clin Physiol Funct Imaging. 2012;32:83–8.PubMedCrossRef
6.
Sorlí-Aguilar M, Martín-Luján F, Flores-Mateo G, Jardí-Piñana C, Aparicio-Llopis E, Basora-Gallisà J, et al. Adiposity markers and lung function in smokers: a cross-sectional study in a Mediterranean population. BMC Pulm Med. 2016;16:178.PubMedPubMedCentralCrossRef
7.
Schweitzer L, Geisler C, Johannsen M, Glüer CC, Müller MJ. Associations between body composition, physical capabilities and pulmonary function in healthy older adults. Eur J Clin Nutr. 2017;71:389–94.PubMedCrossRef
8.
Graffy PM, Pickhardt PJ. Quantification of hepatic and visceral fat by CT and MR imaging: relevance to the obesity epidemic, metabolic syndrome and NAFLD. Br J Radiol. 2016;89:20151024.PubMedPubMedCentralCrossRef
9.
10.
Amato MC, Giordano C, Galia M, Criscimanna A, Vitabile S, Midiri M, et al. Visceral Adiposity Index: a reliable indicator of visceral fat function associated with cardiometabolic risk. Diabetes Care. 2010;33:920–2.PubMedPubMedCentralCrossRef
11.
Pekgor S, Duran C, Berberoglu U, Eryilmaz MA. the role of visceral adiposity index levels in predicting the presence of metabolic syndrome and insulin resistance in overweight and obese patients. Metab Syndr Relat Disord. 2019;17:296–302.PubMedCrossRef
12.
Techatraisak K, Wongmeerit K, Dangrat C, Wongwananuruk T, Indhavivadhana S. Measures of body adiposity and visceral adiposity index as predictors of metabolic syndrome among Thai women with PCOS. Gynecol Endocrinol. 2016;32:276–80.PubMedCrossRef
13.
Wei J, Liu X, Xue H, Wang Y, Shi Z. Comparisons of visceral adiposity index, body shape index, body mass index and waist circumference and their associations with diabetes mellitus in adults. Nutrients. 2019;11:1580.PubMedCentralCrossRef
14.
Xu C, Ma Z, Wang Y, Liu X, Tao L, Zheng D, et al. Visceral adiposity index as a predictor of NAFLD: a prospective study with 4-year follow-up. Liver Int. 2018;38:2294–300.PubMedCrossRef
15.
Dereziński T, Zozulińska-Ziółkiewicz D, Uruska A, Dąbrowski M. Visceral adiposity index as a useful tool for the assessment of cardiometabolic disease risk in women aged 65 to 74. Diabetes Metab Res Rev. 2018;34:e3052.PubMedCrossRef
16.
Bagyura Z, Kiss L, Lux Á, Csobay-Novák C, Jermendy ÁL, Polgár L, et al. Association between coronary atherosclerosis and visceral adiposity index. Nutr Metab Cardiovasc Dis. 2020;30:796–803.PubMedCrossRef
17.
Yeh HC, Punjabi NM, Wang NY, Pankow JS, Duncan BB, Cox CE, et al. Cross-sectional and prospective study of lung function in adults with type 2 diabetes: the Atherosclerosis Risk in Communities (ARIC) study. Diabetes Care. 2008;31:741–6.PubMedCrossRef
18.
Qin L, Zhang W, Yang Z, Niu Y, Li X, Lu S, et al. Impaired lung function is associated with non-alcoholic fatty liver disease independently of metabolic syndrome features in middle-aged and elderly Chinese. BMC Endocr Disord. 2017;17:18.PubMedPubMedCentralCrossRef
19.
Mantovani A, Lonardo A, Vinco G, Zoppini G, Lippi G, Bonora E, et al. Association between non-alcoholic fatty liver disease and decreased lung function in adults: a systematic review and meta-analysis. Diabetes Metab. 2019;45:536–44.PubMedCrossRef
20.
Liu X, Qiu X, Shi C, Huang H, Huang J, Li M, et al. Modified glomerular filtration rate-estimating equations developed in asiatic population for chinese patients with type 2 diabetes. Int J Endocrinol. 2014;2014:521071.PubMedPubMedCentral
21.
Rowe A, Hernandez P, Kuhle S, Kirkland S. The association between anthropometric measures and lung function in a population-based study of Canadian adults. Respir Med. 2017;131:199–204.PubMedCrossRef
22.
Wehrmeister FC, Menezes AM, Muniz LC, Martínez-Mesa J, Domingues MR, Horta BL. Waist circumference and pulmonary function: a systematic review and meta-analysis. Syst Rev. 2012;1:55.PubMedPubMedCentralCrossRef
23.
Chen R, Tunstall-Pedoe H, Bolton-Smith C, Hannah MK, Morrison C. Association of dietary antioxidants and waist circumference with pulmonary function and airway obstruction. Am J Epidemiol. 2001;153:157–63.PubMedCrossRef
24.
25.
Boriek AM, Lopez MA, Velasco C, Bakir AA, Frolov A, Wynd S, et al. Obesity modulates diaphragm curvature in subjects with and without COPD. Am J Physiol Regul Integr Comp Physiol. 2017;313:R620–9.PubMedPubMedCentralCrossRef
26.
Rodrigues GC, Rocha NN, Maia LA, Melo I, Simões AC, Antunes MA, et al. Impact of experimental obesity on diaphragm structure, function, and bioenergetics. J Appl Physiol. 1985;2020(129):1062–74.
27.
Fantuzzi G. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol. 2005;115:911–9 ((quiz 20)).PubMedCrossRef
28.
Unamuno X, Gómez-Ambrosi J, Rodríguez A, Becerril S, Frühbeck G, Catalán V. Adipokine dysregulation and adipose tissue inflammation in human obesity. Eur J Clin Invest. 2018;48:e12997.PubMedCrossRef
29.
Lemieux I, Pascot A, Prud’homme D, Alméras N, Bogaty P, Nadeau A, et al. Elevated C-reactive protein: another component of the atherothrombotic profile of abdominal obesity. Arterioscler Thromb Vasc Biol. 2001;21:961–7.PubMedCrossRef
30.
Ibrahim MM. Subcutaneous and visceral adipose tissue: structural and functional differences. Obes Rev. 2010;11:11–8.PubMedCrossRef
31.
Shaaban R, Kony S, Driss F, Leynaert B, Soussan D, Pin I, et al. Change in C-reactive protein levels and FEV1 decline: a longitudinal population-based study. Respir Med. 2006;100:2112–20.PubMedCrossRef
32.
Lee HM, Le TV, Lopez VA, Wong ND. Association of C-reactive protein with reduced forced vital capacity in a nonsmoking US population with metabolic syndrome and diabetes. Diabetes Care. 2008;31:2000–2.PubMedPubMedCentralCrossRef
33.
Mannino DM, Ford ES, Redd SC. Obstructive and restrictive lung disease and markers of inflammation: data from the Third National Health and Nutrition Examination. Am J Med. 2003;114:758–62.PubMedCrossRef
34.
35.
Park YS, Kwon HT, Hwang SS, Choi SH, Cho YM, Lee J, et al. Impact of visceral adiposity measured by abdominal computed tomography on pulmonary function. J Korean Med Sci. 2011;26:771–7.PubMedPubMedCentralCrossRef
36.
Kwack WG, Kang YS, Jeong YJ, Oh JY, Cha YK, Kim JS, et al. Association between thoracic fat measured using computed tomography and lung function in a population without respiratory diseases. J Thorac Dis. 2019;11:5300–9.PubMedPubMedCentralCrossRef
37.
Chen GP, Qi JC, Wang BY, Lin X, Zhang XB, Zhao JM, et al. Applicability of visceral adiposity index in predicting metabolic syndrome in adults with obstructive sleep apnea: a cross-sectional study. BMC Pulm Med. 2016;16:37.PubMedPubMedCentralCrossRef
38.
Mazzuca E, Battaglia S, Marrone O, Marotta AM, Castrogiovanni A, Esquinas C, et al. Gender-specific anthropometric markers of adiposity, metabolic syndrome and visceral adiposity index (VAI) in patients with obstructive sleep apnea. J Sleep Res. 2014;23:13–21.PubMedCrossRef
39.
Nazare JA, Smith JD, Borel AL, Haffner SM, Balkau B, Ross R, et al. Ethnic influences on the relations between abdominal subcutaneous and visceral adiposity, liver fat, and cardiometabolic risk profile: the International Study of Prediction of Intra-Abdominal Adiposity and Its Relationship With Cardiometabolic Risk/Intra-Abdominal Adiposity. Am J Clin Nutr. 2012;96:714–26.PubMedCrossRef
40.
Lim U, Ernst T, Buchthal SD, Latch M, Albright CL, Wilkens LR, et al. Asian women have greater abdominal and visceral adiposity than Caucasian women with similar body mass index. Nutr Diabetes. 2011;1:e6.PubMedPubMedCentralCrossRef
41.
He H, Ni Y, Chen J, Zhao Z, Zhong J, Liu D, et al. Sex difference in cardiometabolic risk profile and adiponectin expression in subjects with visceral fat obesity. Transl Res. 2010;155:71–7.PubMedCrossRef
42.
Ditomasso D, Carnethon MR, Wright CM, Allison MA. The associations between visceral fat and calcified atherosclerosis are stronger in women than men. Atherosclerosis. 2010;208:531–6.PubMedCrossRef
43.
Tonstad S, Sandvik E, Larsen PG, Thelle D. Gender differences in the prevalence and determinants of the metabolic syndrome in screened subjects at risk for coronary heart disease. Metab Syndr Relat Disord. 2007;5:174–82.PubMedCrossRef
Metadata
Title
Visceral adiposity index is associated with lung function impairment: a population-based study
Authors
Sunyue He
Jie Yang
Xiaoyong Li
Hongxia Gu
Qing Su
Li Qin
Publication date
01-12-2021
Publisher
BioMed Central
Keywords
Obesity
Obesity
Published in
Respiratory Research / Issue 1/2021
Electronic ISSN: 1465-993X
DOI
https://doi.org/10.1186/s12931-020-01599-3

Other articles of this Issue 1/2021

Respiratory Research 1/2021 Go to the issue

Research

SPECT imaging of pulmonary vascular disease in bleomycin-induced lung fibrosis using a vascular endothelium tracer

Research

Validation of a derived version of the IPF-specific Saint George’s Respiratory Questionnaire

Research

Mutational signature analysis in non-small cell lung cancer patients with a high tumor mutational burden

Research

Patient-reported dyspnea and health predict waitlist mortality in patients waiting for lung transplantation in Japan

Letter to the Editor

Post-discharge critical COVID-19 lung function related to severity of radiologic lung involvement at admission

Review

A short primer on lung stereology
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits